Marshall Wace’s Aquestive Therapeutics AQST Stock Holding History

Marshall Wace’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$76K	Buy	+18,315	New	+$74.3K	﹤0.01%	2930
2025 Q4	–	Sell	-371,066	Closed	-$2.07M	–	2932
2025 Q3	$2.07M	Buy	371,066 +298,487	+411%	+$1.29M	﹤0.01%	1596
2025 Q2	$240K	Buy	+72,579	New	+$208K	﹤0.01%	2402
2025 Q1	–	Sell	-55,695	Closed	-$198K	–	2611
2024 Q4	$198K	Buy	+55,695	New	+$257K	﹤0.01%	2354
2024 Q3	–	Sell	-77,016	Closed	-$200K	–	2475
2024 Q2	$200K	Buy	+77,016	New	+$257K	﹤0.01%	2298
2024 Q1	–	Sell	-288,884	Closed	-$584K	–	2414
2023 Q4	$584K	Sell	288,884 -21,925	-7%	-$38.7K	﹤0.01%	1656
2023 Q3	$476K	Buy	310,809 +38,414	+14%	+$66.1K	﹤0.01%	1742
2023 Q2	$449K	Buy	+272,395	New	+$493K	﹤0.01%	2022

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace's AQST Position: Q1 2026 in Review

Marshall Wace opened a new position in Aquestive Therapeutics (AQST) in Q1 2026: 18,315 shares worth $76K. The stake represents ﹤0.01% of the portfolio and ranks #2930 among its holdings. This is a return to the name: Marshall Wace previously reported a position in AQST as recently as Q3 2025.

Marshall Wace first reported a position in AQST in Q2 2023 and has held it in 8 quarters since. The position peaked at $2.07M in Q3 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

Marshall Wace held 18,315 shares of Aquestive Therapeutics worth $76K as of Q1 2026.
Aquestive Therapeutics was a new Marshall Wace position in Q1 2026.
Aquestive Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2930 holding.
Marshall Wace first reported a position in Aquestive Therapeutics in Q2 2023 and has held it in 8 quarters since.
Marshall Wace's Aquestive Therapeutics position peaked at $2.07M in Q3 2025.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.